Royalty Pharma plc (RPRX)

NASDAQ: RPRX · Real-Time Price · USD

61.41

+0.56 (0.92%)

Aug 31, 2026, 4:00 PM EDT - Market closed

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Cystic Fibrosis Franchise Revenue	855.89M	828.18M	826.21M
Evrysdi Revenue	221.14M	206.97M	224.43M
Trelegy Revenue	160.44M	154.10M	146.92M
Tremfya Revenue	191.36M	152.94M	147.14M
Voranigo Revenue	172.98M	154.42M	46.15M
Tysabri Revenue	111.38M	116.88M	124.82M
Other Products Revenue	691.07M	647.67M	633.76M
Total Income from Financial Royalty Assets	2.40B	2.26B	2.15B
Other Royalty Income and Revenue	131.74M	117.04M	114.15M
Revenue (Other)	-172.98M	-154.42M	-46.15M
Revenue (Total)	2.54B	2.38B	2.26B

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Portfolio Receipts	3.39B	3.25B	2.80B